Chimeric antigen receptor T-cell therapy-related T-cell malignancies: raising awareness of cutaneous manifestations
British Journal of Dermatology · 18.11.2025 · 193 (6) · 1232-1233
DOI: 10.1093/bjd/ljaf297 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 17.11.2025. Verfasst von Jonathan J Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
CAR T-cell therapies for blood cancers have recently been associated with secondary T-cell malignancies that can initially present on the skin. We discuss the molecular, immunological and clinical features of these cases and compare them with cutaneous and other T-cell lymphomas. Raising awareness of these secondary neoplasms is important for dermatologists who may be called on for intervention.
Autor:innen und Institutionen
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
ORCID-Profile: Jonathan J Park
Zitieren
APA
Park, J. J., Nguyen, C. V., Choi, J. N., & Guitart, J. (2025). Chimeric antigen receptor T-cell therapy-related T-cell malignancies: raising awareness of cutaneous manifestations. British Journal of Dermatology, 193(6), 1232-1233. https://doi.org/10.1093/bjd/ljaf297
Vancouver
Park JJ, Nguyen CV, Choi JN, Guitart J. Chimeric antigen receptor T-cell therapy-related T-cell malignancies: raising awareness of cutaneous manifestations. British Journal of Dermatology. 2025;193(6):1232-1233. doi:10.1093/bjd/ljaf297
BibTeX
@article{Park2025,
author = {Park, Jonathan J and Nguyen, Cuong V and Choi, Jennifer N and Guitart, Joan},
title = {Chimeric antigen receptor T-cell therapy-related T-cell malignancies: raising awareness of cutaneous manifestations},
journal = {British Journal of Dermatology},
year = {2025},
volume = {193},
number = {6},
pages = {1232--1233},
doi = {10.1093/bjd/ljaf297}
}
EUVIMED